Sigma-Aldrich Fine Chemicals (SAFC) has announced that its pharmaceutical branch has been appointed to deliver current good manufacturing practices (cGMF) of its lead ruthenium cancer therapy compounds.

Speaking at the CPhI Expo in Madrid, SAFC revealed that the wholly-owned cancer therapy subsidiary of the Medical Marketing International (MMI) Group, OncoSense, has chosen SAFC for the manufacturing and distribution of the ruthenium cancer therapy.

Mark Burton, technical manager of MMI, explained to in-Pharma Technologist: "Under the terms of the agreement, OncoSense will retain ownership of all existing and any new intellectual property that arises out of the manufacturing process."

The deal will provide a major platform for the ruthenium cancer therapy and the manufacturing of the new product will begin in the US.

Manufacturing the new therapy in the US is part of an effort to increase awareness in the country, which is considered to have potentially the largest market for the product.

Ruthenium is becoming an increasingly important element in the treatment of illnesses such as cancer, as highlighted by a recent £10 million investment in the MMI to develop its research and manufacturing programmes, including those involving ruthenium.


© Adfero Ltd